# How Should Healthcare AI Vendors Be Evaluated for Due Diligence?

hcco.app · October 2, 2026

> What Healthcare AI Vendor Due Diligence Actually Requires Healthcare AI vendor due diligence is the process of determining whether a company can...

## What Healthcare AI Vendor Due Diligence Actually Requires

Healthcare AI vendor due diligence is the process of determining whether a company can safely, legally, and reliably supply an AI product to a payer, provider, health plan, or benefits organization. The evaluation must cover more than model accuracy or an impressive sales demonstration. Buyers should examine the vendor’s intended use, data flows, security controls, contractual protections, clinical or operational validation, bias testing, incident history, subcontractors, retention practices, and ability to support an adverse decision without shifting all responsibility to the customer. “HIPAA compliant” is a useful starting point, but it is not an independent certification that proves a product is appropriate for every healthcare workflow. As of October 2, 2026, a defensible diligence process should produce evidence that can be reviewed by legal, privacy, security, procurement, compliance, and the business owner rather than relying on a vendor’s unsupported claim.

**Also worth reading:** [What is the definitive AI vendor due diligence checklist for healthcare organizations in 2026?](https://hcco.app/knowledge/what_is_the_definitive_ai_vendor_due_diligence_checklist_for_healthcare_organizations_in_2026.php) · [How Should Healthcare Organizations Rigorously Evaluate SaaS Vendors for Cost Containment and Care Coordination in 2026?](https://hcco.app/knowledge/how_should_healthcare_organizations_rigorously_evaluate_saas_vendors_for_cost_containment_and_care_coordination_in_2026.php) · [What Are the Best Healthcare Savings Benchmarks for Payers and Providers in 2026?](https://hcco.app/knowledge/what_are_the_best_healthcare_savings_benchmarks_for_payers_and_providers_in_2026-2.php)

The central question is not simply whether the AI works, but whether it works consistently for the organization’s populations, data, decisions, and risk tolerance. A model that performs well in a demonstration can still create problems when applied to claims, discharge planning, utilization management, patient messaging, documentation, or care coordination at production volume. A buyer should define the exact decision the system will influence and determine who remains accountable when the output is wrong, delayed, biased, inaccessible, or unavailable. Vendor due diligence is therefore both an evaluation of technology and an allocation of operational risk. The strongest process treats the supplier as one party in a controlled service relationship rather than as an infallible decision maker.

## Security, Privacy, and HIPAA Evidence

Healthcare organizations should ask for current independent security assessments, penetration-test summaries, vulnerability-management metrics, encryption details, access-control evidence, and disaster-recovery results. The relevant HIPAA requirements depend on whether the vendor is a business associate, but covered entities and business associates must address administrative, physical, and technical safeguards under the HIPAA Security Rule. Evidence should include, where applicable, a signed Business Associate Agreement, documented risk analysis, workforce access controls, audit logging, emergency access procedures, backup and restoration practices, and incident-notification terms. A SOC 2 Type II report may provide useful control assurance, but it is not a substitute for HIPAA analysis because a SOC examination evaluates criteria chosen by the service organization, not every healthcare obligation.

Buyers should map the actual data path, including prompts, retrieved records, model inputs, generated outputs, telemetry, support files, logs, backups, and data used for model training. The vendor must explain whether data is retained, whether it is used to improve general or customer-specific models, who can access it, where it is processed, and how long each copy survives. “We do not train on customer data” is a meaningful claim only if contract language, configuration, and technical controls support it. Encryption in transit and at rest should be requested for all sensitive data, along with evidence about tenant separation and privileged-user monitoring. Organizations may also set internal thresholds, such as requiring remediation of critical findings before production access and a defined time for notifying affected customers of a security incident.

## Clinical, Operational, and Fairness Validation

A vendor must demonstrate that its product is valid for the specific population and workflow being purchased. For generative or ambient clinical tools, buyers should request validation studies that compare results with the applicable ground truth, report false-positive and false-negative rates, and explain how performance changes across age, race, ethnicity, language, disability, geography, insurance type, and clinical complexity. For utilization management, prior authorization, denial support, or care-cost tools, performance should be measured at the level of the recommendation or decision, not merely the accuracy of an underlying language model. The 2025-2026 market debate around AI-assisted healthcare decisions makes this distinction especially important: automation can increase consistency, but it can also reproduce historical bias or apply cost objectives in ways that disadvantage vulnerable populations.

Validation should include real or representative test data and a process for monitoring drift after deployment. A credible vendor can identify the intended user, intended use, prohibited uses, escalation path, and circumstances in which the system should defer to a person. For high-impact decisions, an organization may require human review, a documented reason for any override, and a prohibition on fully automated adverse determinations unless counsel and regulators have established a lawful basis and necessary safeguards. Metrics should be translated into operational thresholds. For example, a buyer might require at least 99% availability for an administrative assistant while demanding a separately defined review rate for clinical or coverage recommendations. There is no universal acceptable accuracy percentage; the threshold must reflect the harm, reversibility, and human fallback associated with the use case.

## Contracts, Liability, Exit Planning, and Business Continuity

The contract is where many diligence promises become enforceable obligations. Healthcare buyers should review limitation-of-liability language, indemnification, insurance, breach-notification timing, audit rights, data-return obligations, deletion certification, confidentiality, model-change controls, subcontractor approval, regulatory cooperation, and the vendor’s obligation to preserve records relating to an individual decision. The allocation of responsibility for consequential harm matters greatly when an incorrect recommendation causes delayed care, improper payment, patient harm, or a discrimination complaint. A vendor that disclaims responsibility for model outputs, data errors, and third-party services may be unsuitable for a high-impact deployment even if its product performs well in a pilot.

Contracts should also address the operational consequences of failure. Buyers need to know whether the vendor offers a service-level agreement, what uptime and response commitments are provided, and whether credits are the only remedy. Continuity planning should include exportable data, documented interfaces, transition assistance, deletion on termination, and a realistic estimate of migration time. A reasonable planning assumption is to allow at least 90 days for a complex migration, although the actual period can range from several weeks to more than six months depending on integrations, data volume, and regulatory approvals. Vendors should not be permitted to change the model materially without notice, testing, and an opportunity to reject the change. Model cards, release notes, and subprocessor disclosures should be treated as contractually relevant records rather than optional marketing material.

## Comparing Build, Buy, and Managed Alternatives

Healthcare organizations generally have three routes: build an internal system, buy a specialized vendor product, or use a managed service that combines software with human review. The choice should be driven by data sensitivity, internal technical capacity, clinical accountability, expected decision volume, and the cost of failure. Building may provide greater control over workflows and data but creates recruiting, validation, monitoring, security, and regulatory burdens that persist after launch. Buying can shorten implementation time and provide vendor expertise, but it creates dependency and does not eliminate the customer’s responsibility for selecting the tool and supervising its use. A managed service may be more appropriate for high-volume administrative work if it includes trained reviewers, documented escalation, and clear service guarantees, but human involvement can materially increase price.

| Feature | Internal build | Vendor purchase | Managed service |
| --- | --- | --- | --- |
| Control over workflows | Highest | Moderate to high | Moderate |
| Time to initial deployment | Often 9-24 months | Often 3-12 months | Often 2-8 weeks |
| Direct infrastructure and support cost | High and variable | Subscription plus integration cost | Per-transaction or per-user pricing |
| Liability and model monitoring | Customer carries primary responsibility | Shared under contract | Shared, often with service credits |
| Best fit for differentiated workflows or sensitive data | Common internal platform | Standardized administrative or clinical support | High-volume review with human fallback |
| Main weakness | Talent and maintenance burden | Vendor dependence and hidden fees | Less automation and variable labor usage |

The comparison is not a contest in which one option is universally best. A provider with a mature data-governance and engineering organization may build a narrow internal summarization tool, while a smaller health plan may buy a standard utilization-management product to avoid recruiting a machine-learning team. The buyer should compare total cost over three years, including integration, security reviews, inference or transaction fees, implementation, training, monitoring, human review, contract administration, and exit costs. Cloud AI pricing is usage-dependent; a pilot may cost less than $25,000, while enterprise implementations commonly range from $100,000 to more than $1 million. Operational services can add fees per document, claim, conversation, or reviewed case. These are planning ranges, not universal market prices, and buyers should request a written pricing schedule with overage, minimum-commitment, and renewal provisions.

## Practical Due Diligence in 90 Days

The first stage is to create a cross-functional diligence team and define the use case before requesting a demo. The team should include a business owner, privacy or compliance lead, information-security reviewer, legal counsel, clinician or operations representative, data owner, and procurement lead. During days 1-15, document the intended purpose, affected populations, data categories, decisions, vendors, users, retention needs, and prohibited applications. During days 16-30, request security reports, HIPAA documentation, architecture diagrams, model and dataset documentation, validation results, customer references, insurance information, and a complete subprocessor list. Claims should be converted into evidence requests; for example, “the model is private” should become a written explanation of training data, isolation, logging, retention, and contractual restrictions.

During days 31-60, run a controlled evaluation using sanitized or approved production-like data. The evaluation should include adversarial prompts, missing information, conflicting records, multilingual inputs, accessibility cases, and examples that could lead to harm. Compare the AI output with an experienced human baseline and track error types, latency, uptime, review time, and subgroup performance. During days 61-75, complete legal and commercial review, including breach timelines, liability, indemnity, audit rights, model updates, data deletion, and exit assistance. By day 90, the organization should either approve a limited deployment, require remediation and another review, or reject the product. A limited deployment is often safer than a binary go/no-go decision because it can test integrations and user behavior under measurable controls.

## Common Due Diligence Mistakes

One mistake is treating a polished demonstration as proof of production readiness. Demos usually use clean inputs, selected examples, and a constrained workflow. Another is accepting “HIPAA compliant” without identifying which entity is accountable, what systems are in scope, and what safeguards operate in the vendor’s environment. A second major error is comparing subscription prices rather than total operating cost. Integration work, manual review, data labeling, security remediation, and vendor onboarding can exceed the license fee, particularly when the product processes millions of claims or encounters. Buyers also make the mistake of allowing a model to influence high-impact decisions before establishing an escalation process. This is particularly risky in utilization management, where an AI recommendation can become a denial or delay care even if the system labels itself as assistive.

A further error is asking only about current accuracy and not about model drift. Performance can change after a new EHR, payer policy, coding update, population shift, or change in the vendor’s training pipeline. Contracts and monitoring plans should specify how often performance is reviewed, which thresholds trigger investigation, and when the customer can suspend use. Finally, some organizations conduct diligence but fail to assign owners after purchase. Procurement, IT, compliance, and the business unit should agree in advance who reviews incidents, approves model changes, handles complaints, and decides whether a tool should be retired. Due diligence is not a one-time gate; it is a recurring control.

## When to Act and What Good Governance Looks Like

A buyer should pause procurement when the use case is unclear, the vendor cannot identify all subprocessors, the contract makes privacy commitments vague, or validation results are limited to a narrow demo. For lower-risk functions such as internal search or draft administrative summaries, a shorter review may be reasonable if data is de-identified, outputs are not used for coverage or clinical decisions, and users receive appropriate training. For clinical documentation, care-plan suggestions, prior authorization, payment integrity, or any workflow affecting access to care, the review should include clinical, compliance, and human-fallback analysis. As a practical threshold, a production pilot should not begin until the organization has a documented owner, approved data set, test results, incident route, and contractual permission to use the data.

Good governance creates a continuing record of the product version, approved purpose, validation date, material changes, incidents, user overrides, complaints, and remediation. A quarterly review is a reasonable default for fast-changing systems, while a monthly review may be appropriate for high-volume or high-impact deployments. Organizations should not publish a fixed “safe” accuracy number or claim that AI removes administrative cost without measuring actual outcomes. Total savings should include avoided labor, faster review, fewer denials or appeals, improved patient throughput, implementation expense, and the cost of errors. Healthcare AI can reduce repetitive work and improve consistency, but due diligence determines whether those gains are worth the operational risk. The defensible vendor is not necessarily the one with the most advanced model; it is the one whose evidence, accountability, and contractual behavior remain credible when the use case becomes difficult.

## Quick answers

### Is HIPAA compliance enough for healthcare AI vendor selection?

No. HIPAA compliance is one legal and security consideration, not a universal quality certification. Buyers should separately review intended use, data flows, model validation, bias, subcontractors, incident response, liability, and human oversight. A vendor can sign a Business Associate Agreement and still be a poor fit for a high-impact clinical or coverage decision.

### How long should healthcare AI due diligence take?

A focused review can be completed in about 90 days, but complex integrations may require 6-12 months. The timeline depends on data sensitivity, clinical validation, security remediation, contract negotiations, and the number of systems that must be connected. Complex migrations should also allow several months of transition planning rather than assuming immediate replacement.

### What accuracy should a healthcare AI vendor be required to achieve?

There is no single acceptable percentage because error consequences differ by workflow. A clinical or utilization-management system should be evaluated using subgroup false-positive and false-negative rates, human agreement, severity of errors, and performance under realistic conditions. A low-risk administrative tool may use different thresholds from a tool that influences denials or patient-care decisions.

### Should a healthcare organization build its own AI or buy a vendor product?

Build when the workflow is highly differentiated and the organization has sustained engineering, security, validation, and monitoring capacity. Buy or use a managed service when speed, specialist expertise, and standardized administration matter more than full control. The decision should compare three-year total cost, liability, integration burden, and exit options rather than license price alone.

### What evidence should a healthcare AI vendor provide during procurement?

The vendor should provide a current security assessment, Business Associate Agreement when applicable, architecture and data-flow details, subprocessor list, incident history, model documentation, validation results, bias testing, retention and deletion policies, and customer references. Claims should be supported by technical or contractual evidence, not only by sales statements or a generic statement that the product is HIPAA compliant.

Canonical: https://hcco.app/knowledge/how_should_healthcare_ai_vendors_be_evaluated_for_due_diligence.php
Markdown: https://hcco.app/knowledge/how_should_healthcare_ai_vendors_be_evaluated_for_due_diligence.php/index.md